Yvan Jamilloux, Fleur Cohen-Aubart, Catherine Chapelon-Abric, Delphine Maucort-Boulch, Alicia Marquet, Laurent Pérard, Laurence Bouillet, Alban Deroux, Sébastien Abad, Philip Bielefeld, Diane Bouvry, Marc André, Nicolas Noel, Boris Bienvenu, Alice Proux, Sandra Vukusic, Bahram Bodaghi, Françoise Sarrot-Reynauld, Jean Iwaz, Zahir Amoura, Christiane Broussolle, Patrice Cacoub, David Saadoun, Dominique Valeyre, Pascal Sève
INTRODUCTION: The off-label use of TNF antagonists in refractory sarcoidosis is increasingly reported but data on their efficacy and safety are still insufficient. OBJECTIVE: To report on efficacy and safety of TNF antagonists in severe and refractory sarcoidosis. METHODS: Examination of retrospective demographic, clinical, therapeutic, and adverse event data on 132 sarcoidosis patients (58% women; mean (min-max) age = 45.5 (14-78) years) given TNF antagonists (mainly infliximab, 91%) and investigation of response-linked factors...
October 2017: Seminars in Arthritis and Rheumatism